Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DPhil student Lampros Bisdounis summarises a departmental seminar by Associate Professor Simon Kyle

Interventions for improving chronic sleep disruption

Associate Professor Simon Kyle

16 July 2020, NDCN Seminar

Report by Lampros Bisdounis

In this seminar, Simon Kyle presented the state of affairs on insomnia research and our group’s scientific endeavours to improve current treatment regimens for sleep problems.

Insomnia is defined as a persistent difficulty to initiate or maintain sleep despite adequate opportunity, that results in some form of day-time impairment.. Around one-third of the general population reports acute insomnia symptoms over a 12-month period, while one in ten people experiences chronic sleep problems, making insomnia the second most common mental disorder and the most common sleep disorder. However, insomnia is not simply the clinical presentation of sleeplessness. It is a disorder associated with excessive worry over the consequences of poor sleep, as well as a general disturbance of arousal.

Diagnostically, insomnia relies on the subjective experience of related symptoms. This is due to a misalignment between subjective and objective experiences of sleep and wakefulness. Sleep is clearly and objectively impaired in insomnia. Nevertheless, patients often report much lower total sleep time than what we observe using laboratory measures. Recent advances have shown that instead of mis-perceiving sleep, some insomnia patients might be sensitive to subtle shifts from sleep to wakefulness that are not reflected in standard polysomnographic measurement. Thus, although insomnia is a disorder of objectively measured sleep, it is also a condition not fully appreciated by the existing gold standards of sleep-wake measurements.

Insomnia was traditionally viewed as simply a consequence of the comorbid diagnosis, given that sleep problems are characteristic of the majority of major psychiatric disorders. However, our current understanding is that sleep is also involved in the onset and/or maintenance of psychopathology. In studies using concurrent symptom and rest-activity monitoring, it was evident that sleep disruption is associated with suicidal thoughts, and increased severity of psychotic symptoms the following day. Most importantly, the pathway from sleep to next-day symptoms was stronger than the pathway from day to night.

The prescription of hypnotics is the most common clinical response to insomnia, despite their limited long-lasting effectiveness and despite cognitive behavioural therapy for insomnia (CBT-I) being the recommended first line of treatment. CBT-I is a multi-component treatment involving change in patients’ lifestyle, bedtime behaviours, and dysfunctional beliefs about sleep. Of particular interest to our group is the digital delivery of CBT-I via the Sleepio app. This treatment modality outperforms active placebos and treatment as usual, leading to improvements in both day- and night-time symptoms. Furthermore, to better understand how CBT-I works, we have been investigating the mechanisms of CBT-I, namely sleep restriction therapy (SRT). SRT harnesses the homeostatic sleep drive by reducing and standardising time in bed to increase sleepiness and consolidate sleep. According to our research, SRT effectively increases sleepiness, decreases insomnia severity and leads to enhanced sleep pressure experienced at a more appropriate circadian time.

Future work by our group aims to trial the delivery of SRT by nurses in primary care and assess the benefits of this treatment both for the patient and the healthcare services, refine CBT-I with novel treatment modalities such as bright light therapy and transcranial stimulation, and explore the role of sleep in both mental and physical health conditions.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.